We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Vermillion Announces Notice of Allowance for Peripheral Artery Disease Patent
News

Vermillion Announces Notice of Allowance for Peripheral Artery Disease Patent

Vermillion Announces Notice of Allowance for Peripheral Artery Disease Patent
News

Vermillion Announces Notice of Allowance for Peripheral Artery Disease Patent

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Vermillion Announces Notice of Allowance for Peripheral Artery Disease Patent"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Vermillion, Inc. has announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent entitled "Panel of Biomarkers for Peripheral Artery Disease" to the company.

The patent covers biomarker panels for the diagnosis of Peripheral Artery Disease.

The data supporting the patent were published in an article titled, "A biomarker panel for peripheral arterial disease," in Vasc Med. 2008 Aug; 13(3):217-24.

This work was done in coordination with Dr. John Cooke at Stanford University. Dr. Cooke is Professor and Associate Director of the Stanford Cardiovascular Institute at Stanford University School of Medicine.

"The notice of allowance for this PAD biomarker patent expands our intellectual property portfolio and adds to our first mover advantage. This is an asset the company believes could have significant commercial opportunity as we continue to develop and commercialize our VASCLIR™ test for PAD," said Gail S. Page, CEO of Vermillion.
Advertisement